Skip to content
BillHelp
Menu
YOUR BILLHELP GUIDE

Cancer Treatment Denied by Insurance

What can I do if insurance denies cancer treatment?

A plan can deny cancer treatment or chemotherapy because an approval was missing, because it says the care is not medically necessary, or because it calls the treatment experimental or investigational. The written notice names the reason and the deadline. For many non-grandfathered plans, you can appeal inside the plan, and an urgent appeal has a shorter clock. Medicare covers some chemotherapy, and it covers routine costs of a qualifying clinical trial. This page explains the denial and the appeal. It does not promise payment.

Get help with my bill →
General U.S. guidance. Your plan documents and denial notice explain the process that applies to your case. Medicare, Medicaid, and other programs may use different rules. This is not medical or legal advice, and no result is guaranteed.

What should I read on a cancer treatment denial?

Read the denial for the treatment, the date, and the reason. A missing prior authorization, a finding that the care is not medically necessary, and a label of experimental or investigational are different disputes. HealthCare.gov says a plan may require preauthorization before a service, except in an emergency, and that preauthorization is not a promise of payment. If the notice says approval was missing, see a prior authorization denial. If it says the care is not medically necessary, see a medical necessity denial. If the denied item is a drug the plan handles as a specialty medicine, see a specialty medication denial.

Ask whether the denied service is chemotherapy, another drug, radiation, surgery, or a scan. A PET scan denial has its own Medicare rules. See a PET scan denial. Surgery is in a surgery denial. Do not change the treatment on your own. Ask the oncologist what to do if a dose is coming due.

References: HealthCare.gov: Preauthorization · HealthCare.gov: Internal appeals

What if the plan calls the treatment experimental or off-label?

Ask for the written policy the reviewer used, including the version. HealthCare.gov lists an experimental or investigational decision separately from a medical-necessity decision. The steps for that label are in a claim denied as experimental or investigational. A private plan's policy is its own document. This page does not say that every private plan must use a particular compendium.

Medicare's rule for an off-label anticancer drug is narrower, and it is a Medicare rule. Section 1861(t)(2) of the Social Security Act says a drug used in an anticancer chemotherapeutic regimen for a medically accepted indication includes an FDA-approved use, and it includes another use of an FDA-approved drug when that use is supported by one or more citations in listed compendia, unless the Secretary has determined the use is not medically appropriate or a compendium identifies the use as not indicated. The statute also allows the Medicare contractor to find a use medically accepted from supportive clinical evidence in peer-reviewed literature the Secretary has identified. CMS Transmittal 212, November 6, 2015, states the list in Medicare Benefit Policy Manual, Chapter 15, section 50.4.5, effective for services on or after August 12, 2015: American Hospital Formulary Service-Drug Information, the National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium, Micromedex DrugDex, Clinical Pharmacology, and Wolters Kluwer Lexi-Drugs. The same instruction says a use is generally medically accepted if the indication is NCCN Category 1 or 2A, or DrugDex Class I, IIa, or IIb, or if the narrative in AHFS-DI or Clinical Pharmacology is supportive, or if Lexi-Drugs lists it as off-label and rates it Evidence Level A. It says a use is not medically accepted if it is NCCN Category 3, DrugDex Class III, not supportive in AHFS or Clinical Pharmacology, or listed in Lexi-Drugs as unsupported. The Secretary may revise the list. Ask which compendium and which rating, if any, the denial used. Do not treat that Medicare list as the rule for a private plan unless the plan's own policy adopts it.

References: HealthCare.gov: Internal appeals · Social Security Act section 1861, including anticancer drugs and oral anticancer drugs · CMS Transmittal 212, November 6, 2015: compendia for off-label anticancer drugs, Medicare Benefit Policy Manual chapter 15 section 50.4.5

Does a plan have to cover routine costs in a cancer clinical trial?

Not every charge, and not for every plan. 42 U.S.C. 300gg-8, which is PHS Act section 2709, says that if a group health plan, or a health insurance issuer offering group or individual coverage, covers a qualified individual, it may not deny that person participation in an approved clinical trial. It also may not deny coverage of routine patient costs for items and services furnished in connection with the trial. Routine patient costs are items and services the plan typically covers for someone who is not in a trial. They do not include the investigational item, device, or service itself; items and services provided only to satisfy data collection and analysis and not used in the direct clinical management of the patient; or a service that is clearly inconsistent with widely accepted and established standards of care for a particular diagnosis. The statute limits this rule to an approved trial for cancer or another life-threatening condition, and to a person who qualifies for that trial. 45 CFR 147.140 says this clinical-trial rule does not apply to a grandfathered health plan. There is no separate section of 45 CFR that restates the coverage duty for other plans. The duty is the statute, and 45 CFR 147.140 is the grandfathered-plan exception. Ask the plan which costs it treats as routine. The rest of an experimental denial is in a claim denied as experimental or investigational.

References: 42 U.S.C. 300gg-8: Coverage of routine costs in an approved clinical trial · 45 CFR 147.140: Grandfathered health plans, including the clinical-trial exception

What does Medicare cover for chemotherapy and a clinical trial?

Medicare.gov says Medicare covers chemotherapy if you have cancer. It says Part A covers chemotherapy if you are a hospital inpatient. It says Part B covers chemotherapy if you are a hospital outpatient or you get the services in a doctor's office or a freestanding clinic. After you meet the Part B deductible, Medicare.gov says you typically pay 20% of the Medicare-approved amount for chemotherapy you get in a doctor's office, a freestanding clinic, or a hospital outpatient setting. It says a hospital outpatient copayment will not be more than the inpatient deductible amount. This page does not state that deductible in dollars.

An oral anticancer drug is not automatically the same benefit. Section 1861(s)(2)(Q) of the Social Security Act describes an FDA-approved oral drug prescribed as an anticancer chemotherapeutic agent for a given indication, with the same indication and the same active ingredient as a drug the Medicare contractor determines would be covered under the incident-to provisions if the drug could not be self-administered. 42 CFR 423.100 says a Part D drug does not include a drug for which payment, as prescribed and dispensed or administered, is available under Part A or Part B, even if a deductible applies, and even if the person could have enrolled in Part A or Part B but did not. Ask which part the denial used. A self-administered drug that Part B does not cover can be a Part D question. That appeal is in a prescription drug the plan will not cover.

Clinical trials are separate. National coverage determination 310.1, the version effective May 27, 2024, says that effective for items and services furnished on or after July 9, 2007, Medicare covers the routine costs of qualifying clinical trials, and reasonable and necessary items and services used to diagnose and treat complications from participation in all clinical trials. Routine costs include items and services otherwise generally available to Medicare beneficiaries that are provided in either the experimental or the control arm, except the investigational item or service itself unless it is otherwise covered outside the trial; items and services provided solely for data collection and analysis and not used in direct clinical management; and items and services the research sponsor customarily provides free of charge. The NCD also says a trial must evaluate an item or service in a Medicare benefit category that is not statutorily excluded, must not be designed exclusively to test toxicity or disease pathophysiology and must have therapeutic intent, and must enroll patients with diagnosed disease for a therapeutic trial. Some trials are automatically qualified, including trials funded by NIH, CDC, AHRQ, CMS, the Department of Defense, or the Department of Veterans Affairs, and trials conducted under an FDA investigational new drug application. The current NCD still says Medicare regulations require Medicare+Choice organizations to follow CMS national coverage determinations, that the items and services covered under this NCD must be covered whether or not they are available from in-network providers, and that those organizations cannot require prior authorization or approval. Medicare+Choice is the name in the NCD. 42 CFR 422.101(b)(1) requires a Medicare Advantage organization to comply with CMS national coverage determinations. Medicare.gov says Medicare covers some costs of certain clinical research studies. Ask the study team whether the trial qualifies under NCD 310.1 before you treat a denial of the investigational item as a denial of routine care.

References: Medicare.gov: Chemotherapy · Social Security Act section 1861, including anticancer drugs and oral anticancer drugs · 42 CFR 423.100: Part D drug definition · CMS NCD 310.1: Routine costs in clinical trials, version effective May 27, 2024 · 42 CFR 422.101: Medicare Advantage basic benefits, including traditional Medicare coverage criteria · Medicare.gov: Clinical research studies

How fast is an urgent cancer-treatment appeal?

For a group health plan, 29 CFR 2560.503-1 says a claim involving urgent care must be decided as soon as possible, taking into account the medical exigencies, and not later than 72 hours after the plan receives the claim. A physician with knowledge of your medical condition who determines that the claim is urgent must be treated as having made an urgent claim. An appeal of an urgent-care denial may be submitted orally or in writing, and the plan must decide that appeal as soon as possible and not later than 72 hours after it receives the request for review. The same rule gives you at least 180 days after you receive the denial to appeal. 45 CFR 147.136 applies that claims procedure to non-grandfathered group and individual coverage, and it generally does not apply to a grandfathered plan, except that external review can still apply to some surprise out-of-network emergency, facility, and air-ambulance bills. If the notice gives a later date, use the notice.

HealthCare.gov says that if waiting would seriously jeopardize your life or your ability to regain maximum function, you may file the internal appeal and the external review at the same time. HealthCare.gov also says to request an external review in writing within 4 months after you receive the plan's denial of the internal appeal, when that review is available. A medical-necessity or experimental decision is the kind of medical-judgment dispute that review can cover. The filing steps are in how to request an external review. These clocks are not an approval.

A Medicare Advantage request is different. 42 CFR 422.566 says the enrollee, including a representative, or any provider that furnishes or intends to furnish the services, may request an organization determination. An enrollee or a physician may request that the plan expedite that determination. 42 CFR 422.570 says that expedited request does not include a request for payment of services already furnished. When the plan grants a request to expedite a Part B drug, 42 CFR 422.572 says it must decide as expeditiously as your health requires and no later than 24 hours after it receives the request. For another expedited service request that the plan agrees to expedite, the same section says the decision is due no later than 72 hours after it receives the request. The plan's appeal is in how to appeal a Medicare Advantage denial.

References: 29 CFR 2560.503-1: Claims procedure, including the 180-day appeal period · 45 CFR 147.136: Internal claims, appeals, and external review · HealthCare.gov: Internal appeals · HealthCare.gov: External review · 42 CFR 422.566: Medicare Advantage organization determinations, including who may request one · 42 CFR 422.570: Expedited Medicare Advantage organization determinations · 42 CFR 422.572: Timeframes for expedited Medicare Advantage organization determinations

What can a Medicare Advantage plan require before cancer treatment?

42 CFR 422.101(b) says a Medicare Advantage organization must follow CMS national coverage determinations and general coverage and benefit conditions in traditional Medicare, including the payment criteria for inpatient admissions at 42 CFR 412.3. 42 CFR 422.101(c) says medical-necessity decisions must be based on those coverage criteria, on whether the item is reasonable and necessary, and on the enrollee's medical history, the physician's recommendations, and the clinical notes. The plan may not deny a basic benefit based on criteria outside that section. When Medicare coverage criteria are not fully established, 42 CFR 422.101(b)(6) allows publicly accessible internal criteria that meet the tests in that paragraph. Ask whether the criterion is a national coverage determination, a local coverage determination, or the plan's own policy, and ask for a copy.

42 CFR 422.138 says that when a coordinated care plan uses prior authorization for a basic benefit, it may use that process only to confirm the diagnoses or other medical criteria that support coverage, or to make sure a basic benefit is medically necessary under 42 CFR 422.101(c)(1). If the plan approved the service through prior authorization, or through a pre-service or concurrent decision, it may not later deny coverage for lack of medical necessity, and it may not reopen that decision, except for good cause or if there is reliable evidence of fraud or similar fault. Ask the plan whether the treating clinician can discuss the record with the plan's reviewer. 42 CFR 422.101(c) requires the plan to consider the physician's recommendations and the clinical notes. That discussion does not replace the written appeal, and it does not move the deadline on the notice unless the notice says it does.

References: 42 CFR 422.101: Medicare Advantage basic benefits, including traditional Medicare coverage criteria · 42 CFR 422.138: Medicare Advantage prior authorization

How do I appeal a cancer treatment denial?

Use the notice that matches the decision. For Original Medicare, 42 CFR 405.942 says a redetermination must be filed within 120 calendar days after you receive the notice of the initial determination. Receipt is presumed five calendar days after the date on the notice unless there is evidence otherwise. The steps are in how to appeal an Original Medicare denial. For a private plan, file the internal appeal on the notice. The steps are in how to appeal a health insurance denial. Send the policy the plan named, your oncologist's response to that criterion, and the records that match the use on the prescription. A letter that only says you need care does not answer an experimental-treatment limit.

If the care is urgent, ask the treating clinician to tell the plan, and use the urgent path in the section above. Do not wait for a peer-to-peer call to file if the notice gives a deadline the call does not extend. Nothing on this page says the plan must approve the treatment.

References: 42 CFR 405.942: Original Medicare redetermination filing deadline · Medicare.gov: Appeals in Original Medicare · HealthCare.gov: Internal appeals · U.S. Department of Labor: Filing a claim for your health benefits · 29 CFR 2560.503-1: Claims procedure, including the 180-day appeal period

What this page cannot promise

This is general information, not medical or legal advice. A plan can apply its own experimental-treatment policy. Medicare can deny the investigational item in a trial even when it covers routine costs. A compendium rating can support or refuse a Medicare off-label use. An appeal can leave the denial in place. Nothing on this page promises that a plan or Medicare will cover the treatment or cancel a bill.

Sources and further help

These sources provide general guidance. For a deadline or requirement that applies to you, follow your plan’s notice or the appropriate program’s current instructions.

Insurer websites may ask you to select your state or sign in. If a page will not open, use the member services number on your insurance card and ask for the current appeal instructions for your plan.

Report a broken link or suggest a correction.

← Explore all 141 guides